非肠溶胰酶替代治疗对慢性胰腺炎疼痛的影响:双盲随机对照试验
这项24周双盲安慰剂对照随机试验纳入107例18-60岁慢性胰腺炎伴慢性腹痛成人,随机接受非肠溶胰酶替代治疗(NEPERT)或安慰剂12周。主要结局12周Izbicki疼痛评分变化组间无显著差异(-2.5,95%CI -9.3至4.2,p=0.49),24周结果相似;NEPERT组12周报告疼痛天数比例更高。
要点
- NEPERT未改善慢性胰腺炎患者12周疼痛,主要结局组间无显著差异。
- 24周随访结果与12周一致,未见延迟获益。
- NEPERT组12周报告疼痛天数的比例显著高于安慰剂组。
核心结论
- 在伴有疼痛的慢性胰腺炎成人中,非肠溶胰酶替代治疗(NEPERT)与安慰剂相比未改善疼痛。
研究设计与样本
- 24周双盲、平行组、安慰剂对照随机试验,在两个学术中心纳入107例18-60岁符合Mayo Clinic标准且伴慢性腹痛的慢性胰腺炎成人。
- 主要分析采用重复测量混合效应模型,主要结局为基线至12周Izbicki疼痛评分变化的组间差异。
主要发现
- 意向性治疗分析显示,12周疼痛改善组间无显著差异(Izbicki -2.5,95%CI -9.3至4.2,p=0.49)。
- 24周时结果相似。
- 12周和24周次要结局也相似,但NEPERT组12周报告疼痛天数的参与者比例更高(组间平均差异-14.5,95%CI -26.0至-3.0;p=0.02)。
- 不良事件轻微、自限且组间相当。
临床怎么用
- 对于伴有疼痛的慢性胰腺炎成人,NEPERT不应常规用于镇痛目的。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pain in chronic pancreatitis (CP) is multifactorial. Efficacy of pancreatic enzyme replacement therapy (PERT) for pain remains uncertain. OBJECTIVE: To assess the effect of non-enteric-coated PERT (NEPERT) on pain in CP. DESIGN: In this 24-week, double-blind, placebo-controlled, randomised trial, we enrolled adults aged 18-60 years with CP (Mayo Clinic criteria) and chronic abdominal pain at two academic centres. Participants were randomised to NEPERT (protease 30 000U, lipase 25 000U, amylase 8000U per capsule) or placebo for 12 weeks. Outcomes were measured at 12 and 24 weeks. Primary outcome was between-group differences in change in Izbicki pain score from baseline to 12 weeks. Secondary outcomes were Izbicki and Visual Analogue Scale (for pain) at 24 weeks, painful days, analgesic/hospitalisation requirements, patient's global impression of change and quality of life at 12 and 24 weeks. The reason for secondary outcomes assessment at 24 weeks was to evaluate carry-over effects after NEPERT. Primary analysis used repeated-measures mixed-effects models. RESULTS: 107 patients (mean (SD) age 34.4 (11.4) years; 71% men; 66% idiopathic) were randomised (53 placebo; 54 NEPERT). On intention-to-treat analysis, there were no significant between-group differences in pain improvement at 12 weeks (Izbicki -2.5 (95% CI -9.3 to 4.2), p=0.49). Findings were similar at 24 weeks. Secondary outcomes were also similar at 12 and 24 weeks, except for a higher proportion of participants reporting painful days at 12 weeks in the NEPERT group (mean group differences (95% CI) of -14.5 (-26.0 to -3.0); p=0.02). Adverse events were mild, self-limiting and comparable between groups. CONCLUSIONS: In adults with painful CP, NEPERT did not improve pain compared with placebo. TRIAL REGISTRATION NUMBER: NCT05042284.
引用
- Talukdar R, Rasheed A, Unnisa M, et al. Impact of non-enteric-coated pancreatic enzyme replacement therapy (NEPERT) on pain in patients with chronic pancreatitis: a double-blind, parallel-group, placebo-controlled, randomised trial. Gut. 2026. PMID: 42749363. doi:10.1136/gutjnl-2026-338802
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。